• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过灵敏的酶联免疫吸附测定法评估血液中可溶性程序性死亡受体1、程序性死亡配体1和程序性死亡配体2的稳健分析前性能。

Robust Preanalytical Performance of Soluble PD-1, PD-L1 and PD-L2 Assessed by Sensitive ELISAs in Blood.

作者信息

Krueger Kimberly, Mayer Zsuzsanna, Kottmaier Marc, Gerckens Miriam, Boeck Stefan, Luppa Peter, Holdenrieder Stefan

机构信息

German Heart Center Munich, Clinics at the Technical University Munich, Institute of Laboratory Medicine, Munich Biomarker Research Center, 80636 Munich, Germany.

German Heart Center Munich, Clinics at the Technical University Munich, Department of Cardiovascular Disease, 80636 Munich, Germany.

出版信息

Biomedicines. 2022 Oct 11;10(10):2534. doi: 10.3390/biomedicines10102534.

DOI:10.3390/biomedicines10102534
PMID:36289796
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9598997/
Abstract

The interaction between programmed death-1 receptor PD-1 and its ligands PD-L1 and PD-L2 is involved in self-tolerance, immune escape of cancer, cardiovascular diseases, and COVID-19. As blood-based protein markers they bear great potential to improve oncoimmunology research and monitoring of anti-cancer immunotherapy. A variety of preanalytical conditions were tested to assure high quality plasma sample measurements: (i) different time intervals and storage temperatures before and after blood centrifugation; (ii) fresh samples and repeated freeze-thaw-cycles; (iii) different conditions of sample preparation before measurement. Concerning short-term stability, acceptable recoveries for PD-1 between 80 and 120% were obtained when samples were kept up to 24 h at 4 and 25 °C before and after blood centrifugation. Similarly, recoveries for PD-L2 were acceptable for 24 h at 4 °C and 6 h at 25 °C before blood centrifugation and up to 24 h at 4 and 25 °C after centrifugation. Variations for PD-L1 were somewhat higher, however, at very low signal levels. Sample concentrations (ng/mL) were neither affected by the freezing process nor by repeated freeze-thaw cycles with coefficients of variation for PD-1: 9.1%, PD-L1 6.8%, and PD-L2 4.8%. All three biomarkers showed good stability regarding preanalytic conditions of sample handling enabling reliable and reproducible quantification in oncoimmunology research and clinical settings of anti-cancer immunotherapy.

摘要

程序性死亡-1受体(PD-1)与其配体PD-L1和PD-L2之间的相互作用参与了自身耐受性、癌症免疫逃逸、心血管疾病以及新型冠状病毒肺炎(COVID-19)。作为血液中的蛋白质标志物,它们在改善肿瘤免疫研究和抗癌免疫治疗监测方面具有巨大潜力。为确保高质量的血浆样本测量,测试了多种分析前条件:(i)血液离心前后的不同时间间隔和储存温度;(ii)新鲜样本和反复冻融循环;(iii)测量前不同的样本制备条件。关于短期稳定性,在血液离心前后,样本在4℃和25℃下保存长达24小时时,PD-1的回收率在80%至120%之间,可接受。同样,在血液离心前,PD-L2在4℃下24小时和25℃下6小时的回收率可接受,离心后在4℃和25℃下长达24小时也可接受。然而,在非常低的信号水平下,PD-L1的变化略高。样本浓度(ng/mL)既不受冷冻过程的影响,也不受反复冻融循环的影响,PD-1、PD-L1和PD-L2的变异系数分别为9.1%、6.8%和4.8%。在肿瘤免疫研究和抗癌免疫治疗的临床环境中,所有这三种生物标志物在样本处理的分析前条件方面均表现出良好的稳定性,能够实现可靠且可重复的定量分析。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5818/9598997/5c0e5c8176d7/biomedicines-10-02534-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5818/9598997/3ee4be7992fe/biomedicines-10-02534-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5818/9598997/95304a7a1095/biomedicines-10-02534-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5818/9598997/d9a9356e9c98/biomedicines-10-02534-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5818/9598997/dfbd1dd2ff0b/biomedicines-10-02534-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5818/9598997/5c0e5c8176d7/biomedicines-10-02534-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5818/9598997/3ee4be7992fe/biomedicines-10-02534-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5818/9598997/95304a7a1095/biomedicines-10-02534-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5818/9598997/d9a9356e9c98/biomedicines-10-02534-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5818/9598997/dfbd1dd2ff0b/biomedicines-10-02534-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5818/9598997/5c0e5c8176d7/biomedicines-10-02534-g005.jpg

相似文献

1
Robust Preanalytical Performance of Soluble PD-1, PD-L1 and PD-L2 Assessed by Sensitive ELISAs in Blood.通过灵敏的酶联免疫吸附测定法评估血液中可溶性程序性死亡受体1、程序性死亡配体1和程序性死亡配体2的稳健分析前性能。
Biomedicines. 2022 Oct 11;10(10):2534. doi: 10.3390/biomedicines10102534.
2
High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood.用于血液中可溶性PD-1、PD-L1和PD-L2灵敏定量的新型免疫测定法的高质量性能
Biomedicines. 2022 Sep 26;10(10):2405. doi: 10.3390/biomedicines10102405.
3
Methodological and preanalytical evaluation of a RAGE immunoassay.RAGE 免疫测定法的方法学和预分析评估。
Anticancer Res. 2012 May;32(5):2075-8.
4
Strong impact on plasma protein profiles by precentrifugation delay but not by repeated freeze-thaw cycles, as analyzed using multiplex proximity extension assays.使用多重邻近延伸分析发现,预离心延迟而不是反复冻融循环对血浆蛋白图谱有强烈影响。
Clin Chem Lab Med. 2018 Mar 28;56(4):582-594. doi: 10.1515/cclm-2017-0648.
5
Pan-cancer Landscape of Programmed Death Ligand-1 and Programmed Death Ligand-2 Structural Variations.泛癌种程序性死亡配体-1 和程序性死亡配体-2 结构变异全景。
JCO Precis Oncol. 2023 Jan;7:e2200300. doi: 10.1200/PO.22.00300.
6
Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid.前言变量对阿尔茨海默病患者脑脊液生物标志物浓度的重要性和影响。
Clin Chem. 2015 May;61(5):734-43. doi: 10.1373/clinchem.2014.236679. Epub 2015 Apr 13.
7
Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.淋巴恶性肿瘤中的可溶性程序性死亡蛋白 1(sPD-1)和可溶性程序性死亡配体 1 和 2(sPD-L1 和 sPD-L2)。
Eur J Haematol. 2021 Jul;107(1):81-91. doi: 10.1111/ejh.13621. Epub 2021 Apr 12.
8
Methodological and preanalytical evaluation of an HMGB1 immunoassay.HMGB1 免疫测定的方法学和前分析评估。
Anticancer Res. 2012 May;32(5):2059-62.
9
Missing prognostic value of soluble PD-1, PD-L1 and PD-L2 in lung cancer patients undergoing chemotherapy - A CEPAC-TDM biomarker substudy.在接受化疗的肺癌患者中可溶性 PD-1、PD-L1 和 PD-L2 的预后价值缺失 - CEPAC-TDM 生物标志物子研究。
Tumour Biol. 2024;46(s1):S355-S367. doi: 10.3233/TUB-230015.
10
Multiplex Immuno-Liquid Chromatography-Mass Spectrometry-Parallel Reaction Monitoring (LC-MS-PRM) Quantitation of CD8A, CD4, LAG3, PD1, PD-L1, and PD-L2 in Frozen Human Tissues.多重免疫液相色谱-质谱联用法-平行反应监测(LC-MS-PRM)定量检测冷冻人组织中的 CD8A、CD4、LAG3、PD1、PD-L1 和 PD-L2。
J Proteome Res. 2018 Nov 2;17(11):3932-3940. doi: 10.1021/acs.jproteome.8b00605. Epub 2018 Oct 11.

引用本文的文献

1
Disulfidptosis-related genes serve as potential prognostic biomarkers and indicate tumor microenvironment characteristics and immunotherapy response in prostate cancer.二硫键相关基因可作为潜在的预后生物标志物,提示前列腺癌的肿瘤微环境特征和免疫治疗反应。
Sci Rep. 2024 Jun 19;14(1):14107. doi: 10.1038/s41598-024-61679-y.

本文引用的文献

1
High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood.用于血液中可溶性PD-1、PD-L1和PD-L2灵敏定量的新型免疫测定法的高质量性能
Biomedicines. 2022 Sep 26;10(10):2405. doi: 10.3390/biomedicines10102405.
2
Platelets upregulate tumor cell programmed death ligand 1 in an epidermal growth factor receptor-dependent manner in vitro.血小板在体外通过表皮生长因子受体依赖的方式上调肿瘤细胞程序性死亡配体 1。
Blood Adv. 2022 Oct 25;6(20):5668-5675. doi: 10.1182/bloodadvances.2021006120.
3
Soluble PD-L1 as an early marker of progressive disease on nivolumab.
可溶性 PD-L1 作为纳武利尤单抗治疗进展期疾病的早期标志物。
J Immunother Cancer. 2022 Feb;10(2). doi: 10.1136/jitc-2021-003527.
4
Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials.PD-1 阻断与化疗在 PD-L1 亚组中的关键时间点的反应率和生存:转移性 NSCLC 试验的荟萃分析。
JNCI Cancer Spectr. 2021 Jan 27;5(3). doi: 10.1093/jncics/pkab012. eCollection 2021 Jun.
5
Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer.循环生物标志物在肺癌免疫检查点抑制剂治疗中的整合应用
Cancers (Basel). 2020 Dec 3;12(12):3625. doi: 10.3390/cancers12123625.
6
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors.免疫检查点抑制剂癌症免疫治疗的预测生物标志物。
Biomark Res. 2020 Aug 26;8:34. doi: 10.1186/s40364-020-00209-0. eCollection 2020.
7
Elucidation of stability profiles of common chemistry analytes in serum stored at six graded temperatures.阐明在六种不同温度下储存的血清中常见化学分析物的稳定性特征。
Clin Chem Lab Med. 2019 Aug 27;57(9):1388-1396. doi: 10.1515/cclm-2018-1109.
8
Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy.监测检查点抑制剂:免疫治疗中的预测生物标志物。
Front Med. 2019 Feb;13(1):32-44. doi: 10.1007/s11684-018-0678-0. Epub 2019 Jan 24.
9
Immune checkpoint inhibitors: recent progress and potential biomarkers.免疫检查点抑制剂:最新进展与潜在生物标志物。
Exp Mol Med. 2018 Dec 13;50(12):1-11. doi: 10.1038/s12276-018-0191-1.
10
Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment-are we barking up the wrong tree?程序性细胞死亡配体-1(PD-L1)作为非小细胞肺癌(NSCLC)治疗的生物标志物——我们找错方向了吗?
Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S275-S279. doi: 10.21037/tlcr.2018.04.18.